Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXG202 in wAMD
NCT06888492Phase 1Not yet recruiting
- Sponsor
- Hangzhou Jiayin Biotech
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of EXG202 in exudative macular degeneration (2 arms), sponsored by Hangzhou Jiayin Biotech. Primary endpoint: Safety and tolerability after EXG202 injection at 52 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
EXG202
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06888492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888492.